F. Hirayama

发表

Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor.

K. Mori, T. Kadokura, Yuji Koga, 2011, Journal of medicinal chemistry.

AKR‐501 (YM477) a novel orally‐active thrombopoietin receptor agonist

T. Nakahata, Ken‐ichi Suzuki, Y. Iwatsuki, 2009, European journal of haematology.

AKR-501 (YM477) in combination with thrombopoietin enhances human megakaryocytopoiesis.

Ken‐ichi Suzuki, Y. Iwatsuki, T. Kawasaki, 2008, Experimental hematology.

4-Aminopyridine-2,3-dicarboxylic acid from Clitocybe acromelalga

H. Shirahama, K. Konno, F. Hirayama, 1989 .

Antithrombotic effects of YM‐60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time

Y. Matsumoto, T. Kawasaki, F. Hirayama, 1998, British journal of pharmacology.

YM-60828, a novel factor Xa inhibitor: separation of its antithrombotic effects from its prolongation of bleeding time.

Y. Matsumoto, T. Kawasaki, F. Hirayama, 1997, European journal of pharmacology.

Production of antibiotics by Pseudomonas cepacia as an agent for biological control of soilborne plant pathogens

H. Shirahama, K. Konno, F. Hirayama, 1989 .

Potent and selective TF/FVIIa inhibitors containing a neutral P1 ligand.

M. Okada, T. Niimi, M. Ohta, 2006, Bioorganic & medicinal chemistry.

Antithrombotic effect of YM-75466 is separated from its effect on bleeding time and coagulation time.

Y. Matsumoto, T. Kawasaki, F. Hirayama, 1998, European journal of pharmacology.

Antithrombotic effects of YM-60828 in three thrombosis models in guinea pigs.

Y. Matsumoto, T. Kawasaki, F. Hirayama, 1998, European journal of pharmacology.

Biochemical and Pharmacological Characterization of YM-60828, a Newly Synthesized and Orally Active Inhibitor of Human Factor Xa

M. Kayama, Y. Matsumoto, T. Kawasaki, 1998, Thrombosis and Haemostasis.

Synthesis and biological activity of novel 1,4-diazepane derivatives as factor Xa inhibitor with potent anticoagulant and antithrombotic activity.

Y. Matsumoto, T. Kawasaki, S. Tsukamoto, 2004, Bioorganic & medicinal chemistry.

Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats.

Y. Matsumoto, T. Kawasaki, F. Hirayama, 1998, European journal of pharmacology.

Design, synthesis and biological activity of selective and orally available TF/FVIIa complex inhibitors containing non-amidine P1 ligands.

M. Okada, T. Niimi, M. Ohta, 2007, Bioorganic & medicinal chemistry.

Identification of potent orally active factor Xa inhibitors based on conjugation strategy and application of predictable fragment recommender system.

Yuji Koga, Y. Iwatsuki, F. Hirayama, 2015, Bioorganic & medicinal chemistry.

Novel strategy to boost oral anticoagulant activity of blood coagulation enzyme inhibitors based on biotransformation into hydrophilic conjugates.

K. Mori, Yuji Koga, Y. Iwatsuki, 2014, Bioorganic & medicinal chemistry.

Synthesis and biological activity of novel 1,2-disubstituted benzene derivatives as factor Xa inhibitors.

N. Katayama, Y. Matsumoto, Y. Iwatsuki, 2005, Bioorganic & medicinal chemistry.

Prodrug-based design, synthesis, and biological evaluation of N-benzenesulfonylpiperidine derivatives as novel, orally active factor Xa inhibitors.

M. Orita, Y. Matsumoto, Y. Iwatsuki, 2007, Bioorganic & medicinal chemistry.

The discovery of YM-60828: a potent, selective and orally-bioavailable factor Xa inhibitor.

H. Kurihara, N. Katayama, Y. Matsumoto, 2002, Bioorganic & medicinal chemistry.

Comparative Studies of an Orally-active Factor Xa Inhibitor, YM-60828, with other Antithrombotic Agents in a Rat Model of Arterial Thrombosis

Y. Matsumoto, T. Kawasaki, F. Hirayama, 1998, Thrombosis and Haemostasis.

Effect of a Synthetic Factor Xa Inhibitor, YM-60828, on Blood Vessel Patency in Combination with a Thrombolytic Agent and on Blood Loss from the Operation Site in a Rat Model of Arterial Thrombosis

Y. Matsumoto, T. Kawasaki, F. Hirayama, 1998, Thrombosis and Haemostasis.

Comparison of the anticoagulant and antithrombotic effects of YM-75466, a novel orally-active factor Xa inhibitor, and warfarin in mice.

Y. Matsumoto, T. Kawasaki, F. Hirayama, 1998, Japanese journal of pharmacology.

Design, synthesis and biological activity of YM-60828 derivatives: potent and orally-bioavailable factor Xa inhibitors based on naphthoanilide and naphthalensulfonanilide templates.

H. Kurihara, N. Katayama, Y. Matsumoto, 2002, Bioorganic & medicinal chemistry.

The discovery of YM-60828: a potent, selective and orally-bioavailable factor Xa inhibitor.

H. Kurihara, N. Katayama, Y. Matsumoto, 2002, Bioorganic & Medicinal Chemistry.

An easy access to 7-methyl-2-naphthalenecarbonitrile.

Hiroyoshi Yamada, Y. Matsumoto, F. Hirayama, 2005, Chemical & pharmaceutical bulletin.

Orally active factor Xa inhibitor: synthesis and biological activity of masked amidines as prodrugs of novel 1,4-diazepane derivatives.

Y. Matsumoto, Y. Iwatsuki, T. Kawasaki, 2004, Bioorganic & medicinal chemistry.

Pharmacological profile of AS1670542, a novel orally-active human thrombopoietin receptor agonist.

Ken‐ichi Suzuki, Yuji Koga, T. Kawasaki, 2011, European journal of pharmacology.

Biochemical and Pharmacological Profiles of YM150, an Oral Direct Factor Xa Inhibitor.

Y. Iwatsuki, T. Kawasaki, Yumiko Moritani, 2006 .

Design, synthesis and biological activity of YM-60828 derivatives. Part 2: potent and orally-bioavailable factor Xa inhibitors based on benzothiadiazine-4-one template.

H. Kurihara, N. Katayama, Y. Matsumoto, 2003, Bioorganic & medicinal chemistry.

YM477, a Novel Orally-Active Thrombopoietin Receptor Agonist.

T. Nakahata, H. Hiramatsu, T. Kawasaki, 2005 .

Antithrombotic effects of YM466, a synthesized direct inhibitor of factor Xa, in an arterio‐venous shunt thrombosis model in squirrel monkeys

Y. Matsumoto, Y. Iwatsuki, T. Kawasaki, 2003 .